Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 7/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109403 | 0.95 | KDM1A (0.76) | KDM1AMEN1KMT2AMAOAPOLB | |
| SCHEMBL13109404 | 0.91 | KDM1A (0.78) | KDM1AMEN1KMT2AMAOA | |
| SCHEMBL3451075 | 0.89 | KDM1A (0.83) | KDM1AMAOANPSR1 | |
| SCHEMBL3451888 | 0.88 | NPSR1 (0.76) | KDM1AMEN1KMT2AMAOAPOLB | |
| SCHEMBL3452766 | 0.87 | KDM1A (0.61) | KDM1AMEN1KMT2AMAOAPOLB | |
| SCHEMBL3452443 | 0.87 | KDM1A (0.81) | KDM1AMAOA | |
| SCHEMBL16798757 | 0.87 | KDM1A (0.82) | KDM1AMEN1KMT2AMAOAPOLB | |
| SCHEMBL3452207 | 0.86 | KDM1A (0.62) | KDM1AMEN1KMT2AMAOA | |
| SCHEMBL3452719 | 0.86 | KDM1A (0.59) | KDM1AMEN1KMT2AMAOA | |
| SCHEMBL3453672 | 0.86 | MAPT (0.69) | KDM1AMEN1KMT2AMAOAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | KDM1A 2868/4885MEN1 1990/4885KMT2A 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.